相关实验视频

Updated: Sep 10, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

CD44v6 CAR- T 细胞目标 DNMT3A- 突变性AML:通过Decitabine进行协同增强

Hui-Min Li¹, Yi-Mei Que¹, Xiao-Ya Cai¹

¹Department of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, China.

Current medical science

|August 25, 2025

概括

针对CD44v6的化学抗原受体T细胞 (CAR- T) 疗法在具有DNMT3A突变的急性髓性白血病 (AML) 中具有前景. 通过增加AML细胞的CD44v6表达,增强了decitabine的CAR- T疗效.

科学领域:

血液学
免疫学
癌症学

背景情况:

急性髓性白血病 (AML) 是一种与DNMT3A突变相关的异质癌症.
新的治疗策略对于DNMT3A突变AML至关重要.
CD44v6被认为是一种潜在的治疗点.

研究的目的:

在DNMT3A突变AML中研究CD44v6作为CAR- T治疗的点.
评估CD44v6导向的CAR-T细胞对DNMT3A突变AML的疗效.
评估德西他和CD44v6CAR-T疗法的协同效应.

主要方法:

与CD44v6表达相关的DNMT3A突变状态.
构建了CD44v6CAR-T细胞并对细胞毒性进行了测试.
评估了decitabine对CD44v6表达和CAR- T疗效的影响.

主要成果:

DNMT3A突变AML细胞显示CD44v6表面表达增加.
CD44v6 CAR- T 细胞表现出特定的杀死 DNMT3A 突变的 AML 细胞.
德西塔治疗前增强了CAR- T细胞介导的CD44v6细胞毒性,并提高了CD44v6的表达.

结论:

在DNMT3A突变AML中,CD44v6是可行的CAR- T治疗点.
通过增加标表达来增强CD44v6的CAR-T疗法.
这种组合疗法为一组AML患者提供了有前途的治疗方法.

关键词:

DNMT3A突变急性骨髓性白血病在CD44v6 化学抗原受体组合疗法 DNA 甲基化德西塔表观遗传调节

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...